Are GLP-1s the first true longevity therapies? A new era of prevention

This video summarises the editorial “Are GLP-1s the first longevity drugs?” published in Nature Biotechnology (2025, https://www.nature.com/articles/s41587-025-02932-1). GLP-1 receptor agonists began as treatments for obesity and type 2 diabetes. But the last few years have revealed something far bigger: across multiple major trials, these drugs improve a wide range of age-related conditions, from cardiovascular disease and kidney decline to liver disease, sleep apnea, osteoarthritis and even all-cause mortality in high-risk groups. This unexpected breadth of benefit has triggered a serious question in the ageing field: are GLP-1s the first medicines that genuinely target multiple pathways of ageing?